The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On March 13, Lifeward received shareholder approval to finalize a strategic partnership with Oramed. The partnership grants Lifeward access to up to $47 million in capital. Lifeward will integrate Oramed's POD™ oral delivery technology into its platform.